Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: A viable option?

Pediatric Drugs

Volumn 13, Issue 1, 2011, Pages 49-69

  Höcker, Britta ^a   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ARTICLE; CHILDHOOD DISEASE; DISEASE ASSOCIATION; DRUG SAFETY; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PEDIATRICS; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; RISK ASSESSMENT;

ADULT; CALCINEURIN; CHILD; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TOR SERINE-THREONINE KINASES;

EID: 78650313824     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11538530-000000000-00000     Document Type: Article

References (74)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004 Aug; 4 (8): 1289-95
2. Lamb KE, Lodhi S,Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. Epub 2010 Oct 25
3. Höcker B, Tonshoff B. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview. Paediatr Drugs 2009; 11 (6): 381-96
4. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003 Dec 11; 349 (24): 2326-33
5. North American Pediatric Renal Trials and Collaborative Studies 2008 annual report [online]. Available from URL: http://www.NAPRTCS.org [Accessed 2009 Aug]
6. UpToDate. Clinical practice guidelines: table UTD grading criteria [online]. Available from URL: http://www.uptodate.com [Accessed 2010 Feb 18]
7. Benfield MR, Tejani A, Harmon WE, et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatr Transplant 2005 Jun; 9 (3): 282-92
8. Guba M, Rentsch M, Wimmer CD, et al. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil. Transpl Int 2008 Jul; 21 (7): 637-45
9. Khositseth S, Matas A, Cook ME, et al. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report. Transplantation 2005 Apr 27; 79 (8): 958-63
10. Colleen Hastings M, Wyatt RJ, Lau KK, et al. Five years experience with thymoglobulin induction in a pediatric renal transplant population. Pediatr Transplant 2006 Nov; 10 (7): 805-10
11. Baron PW, Ojogho ON, Yorgin P, et al. Comparison of outcomes with lowdose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: a retrospective study. Pediatr Transplant 2008 Feb; 12 (1): 32-9
12. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001 May 15; 71 (9): 1282-7
13. Asberg A, Midtvedt K, Line PD, et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006 Jul 15; 82 (1): 62-8
14. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002 Dec 27; 74 (12): 1725-34
15. Schnuelle P, van der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002 Feb; 13 (2): 536-43
16. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002 May; 13 (5): 1365-73
17. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007 Mar; 7 (3): 560-70
18. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005 Feb 27; 79 (4): 466-75
19. Harmon W, Meyers K, Ingelfinger J, et al. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006 Jun; 17 (6): 1735-45
20. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008 Jul; 8 (7): 1529-36
21. Ellis D, Shapiro R, Moritz M, et al. Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. Transplantation 2007 Jun 27; 83 (12): 1563-70
22. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, doubleblind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997 Jan 15; 63 (1): 39-47
23. Jungraithmayr T, Staskewitz A, Kirste G, et al., German Pediatric Renal Transplantation Study Group. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 2003 Feb 27; 75 (4): 454-61
24. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005 Jul; 16 (7): 2234-40
25. Cransberg K, Cornelissen M, Lilien M, et al. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk. Transplantation 2007 Apr 27; 83 (8): 1041-7
26. Krischock L, Gullett A, Bockenhauer D, et al. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection. Pediatr Transplant 2009 Jun; 13 (4): 475-81
27. David-Neto E, Araujo LM, Lemos FC, et al. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 2001 Aug; 5 (4): 302-9
28. Kerecuk L, Horsfield C, Taylor J. Improved long-term graft function in pediatric transplant renal recipients with chronic allograft nephropathy. Pediatr Transplant 2009 May; 13 (3): 324-31
29. Filler G, Gellermann J, Zimmering M, et al. Effect of adding mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. Transpl Int 2000; 13 (3): 201-6
30. Tapia E, Franco M, Sanchez-Lozada LG, et al. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int 2003 Mar; 63 (3): 994-1002
31. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005; 28 (2): 153-81
32. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006 Aug; 5 (8): 671-88
33. Rubinsztein DC, Gestwicki JE, Murphy LO, et al. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007 Apr; 6 (4): 304-12
34. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Aktdependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004 Jun; 10 (6): 594-601
35. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 2007 Oct; 82 (4): 381-8
36. Chapman JR, Valantine H, Albanell J, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007 Dec; 39 (10): 2937-50
37. Gaumann A, Schlitt HJ, Geissler EK. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transpl Int 2008 Mar; 21 (3): 207-17
38. Höcker B, Feneberg R, Kopf S, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006 Aug; 10 (5): 593-601
39. Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant 2007 Jul-Aug; 21 (4): 460-5
40. Stallone G, Infante B, Grandaliano G, et al. Management of side effects of sirolimus therapy. Transplantation 2009 Apr 27; 87 (8 Suppl.): S23-6
41. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005 Oct; 5 (10): 2521-30
42. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimusassociated interstitial pneumonitis in renal transplant patients. Transplantation 2001 Sep 15; 72 (5): 787-90
43. Garrean S, Massad MG, Tshibaka M, et al. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005 Oct; 19 (5): 698-703
44. Chhajed PN, Dickenmann M, Bubendorf L, et al. Patterns of pulmonary complications associated with sirolimus. Respiration 2006; 73 (3): 367-74
45. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004Nov 15; 78 (9): 1362-6
46. Kahan BD. Sirolimus-based immunosuppression: present state of the art. J Nephrol 2004 Nov-Dec; 17 Suppl. 8: S32-9
47. Fritsche L, Budde K, Dragun D, et al. Testosterone concentrations and sirolimus in male renal transplant patients.AmJ Transplant 2004 Jan; 4 (1): 130-1
48. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007 Apr; 20 (4): 305-11
49. Tenderich G, Fuchs U, Zittermann A, et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007 Jul-Aug; 21 (4): 536-43
50. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009 Jul 15; 88 (1): 69-76
51. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev 2006; 20 (1): 1-18
52. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999 Apr 15; 67 (7): 1036-42
53. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000 Apr 15; 69 (7): 1252-60
54. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006 Mar; 6 (3): 514-22
55. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007 Apr 15; 83 (7): 883-92
56. Hamdy AF, Bakr MA, Ghoneim MA. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J Am Soc Nephrol 2008 Jun; 19 (6): 1225-32
57. Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008 Feb 15; 85 (3): 486-90
58. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 Dec 20; 357 (25): 2562-75
59. Hamdy AF, El-Agroudy AE, Bakr MA, et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 2005 Oct; 5 (10): 2531-8
60. Lloberas N, Torras J, Alperovich G, et al. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant 2008 Oct; 23 (10): 3111-9
61. Oberbauer R, Kreis H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003 Jul 27; 76 (2): 364-70
62. Budde K, Becker T, Arns W, et al. Analysis of renal function in everolimus/ enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS study [abstract]. Am J Transplant 2009; 9: 259
63. Pietruck F, Becker T, Arns W, et al. Efficacy and safety of an everolimus/ enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant recipients: results of the ZEUS trial [abstract]. Am J Transplant 2009; 9: 499
64. Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine doseminimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003 Apr 27; 75 (8): 1404-8
65. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005 Dec; 16 (12): 3755-62
66. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005 Oct; 5 (10): 2496-503
67. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009 Jan 27; 87 (2): 233-42
68. Hymes LC, Warshaw BL, Amaral SG, et al. Tacrolimus withdrawal and conversion to sirolimus at three months post-pediatric renal transplantation. Pediatr Transplant 2008 Nov; 12 (7): 773-7
69. Powell HR, Kara T, Jones CL. Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol 2007 Oct; 22 (10): 1773-7
70. Falger JC, Mueller T, Arbeiter K, et al. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006 Jun; 10 (4): 474-8
71. Ibanez JP, Monteverde ML, Diaz MA, et al. Sirolimus in chronic allograft nephropathy in pediatric recipients. Pediatr Transplant 2007Nov; 11 (7): 777-80
72. Weintraub L, Li L, Kambham N, et al. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. Pediatr Transplant 2008 Aug; 12 (5): 541-9
73. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004 Nov; 4 (11): 1869-75 (Pubitemid 39434449)
74. Diekmann F, Budde K, Slowinski T, et al. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transpl Int 2008 Feb; 21 (2): 152-5